NCT04477772 - A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

March 14, 2024

Study Completion Date

March 14, 2024

Conditions

Recurrent/Refractory Malignant Lymphoma

Interventions

BIOLOGICAL

JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

Part A: including dose escalation (1mg/kg JS004; 3mg/lg JS004; 10mg/kg JS004), dose expansion (3mg/kg JS004 and 200mg JS004) and indication expansion. Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.

BIOLOGICAL

Drug：JS001, Intravenous infusion

Part B: including dose escalation (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001), dose expansion (240mg JS004+100mg JS001; 240mg JS004+ 200mg JS001) and indication expansion.

Trial Locations (1)

Unknown

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Shanghai Junshi Bioscience Co., Ltd.

OTHER